Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 9.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,431 shares of the company’s stock after purchasing an additional 458 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Vaxcyte were worth $440,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. AQR Capital Management LLC lifted its holdings in Vaxcyte by 3.1% in the second quarter. AQR Capital Management LLC now owns 10,860 shares of the company’s stock valued at $820,000 after acquiring an additional 328 shares during the period. Creative Planning lifted its holdings in Vaxcyte by 64.0% in the second quarter. Creative Planning now owns 27,280 shares of the company’s stock valued at $2,060,000 after acquiring an additional 10,642 shares during the period. SG Americas Securities LLC lifted its holdings in Vaxcyte by 306.9% in the third quarter. SG Americas Securities LLC now owns 9,530 shares of the company’s stock valued at $1,089,000 after acquiring an additional 7,188 shares during the period. Riverview Trust Co acquired a new stake in Vaxcyte in the third quarter valued at $27,000. Finally, Blue Trust Inc. lifted its holdings in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PCVX shares. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $145.71.

Insider Activity

In related news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,472,066.41. This represents a 6.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total transaction of $457,450.00. Following the sale, the senior vice president now directly owns 28,697 shares of the company’s stock, valued at approximately $2,625,488.53. This trade represents a 14.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,982 shares of company stock valued at $5,651,725 in the last 90 days. 3.10% of the stock is currently owned by insiders.

Vaxcyte Trading Down 4.0 %

Shares of PCVX stock opened at $84.81 on Tuesday. The firm has a 50-day moving average price of $87.60 and a 200 day moving average price of $94.38. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06. The company has a market capitalization of $10.57 billion, a price-to-earnings ratio of -18.44 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) earnings per share. As a group, research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.